Eugenol

Chemical Class	Phenylpropanoid (allylbenzene phenol)
Molecular Formula / CAS	C₁₀H₁₂O₂ · CAS 97-53-0
Primary Botanical Source(s)	Clove (Syzygium aromaticum); also cinnamon, nutmeg, tulsi and bay leaf
Plant Part	Flower bud (clove)
Typical Content	The dominant constituent of clove essential oil, typically comprising 70–90% of clove bud oil
Solubility / Format	Oil-soluble; available as a high-purity standardised liquid
Sourcing Status	Product-live — genuine match via Herbuno’s clove extract line
Buy from Herbuno	Eugenol 98% Liquid (Clove Extract)

Name origin: Eugenol takes its name from the historical botanical name for clove, Eugenia caryophyllata (now reclassified as Syzygium aromaticum), itself honouring Prince Eugene of Savoy, an 18th-century patron of botanical science. Traditional use: Clove has one of the longest and most specific traditional dental applications of any HerbIQ compound — whole cloves or clove oil have been placed directly on aching teeth across Chinese, Ayurvedic and European folk medicine for centuries, a use that predates any understanding of eugenol’s local anaesthetic mechanism by well over a thousand years. Research trajectory: Eugenol’s local anaesthetic and analgesic properties were characterised through the 20th century and it became a standard component of dental cement, filling material and temporary restorative compounds; more recent research has expanded into cardiovascular, antimicrobial and antioxidant pharmacology, with a growing body of randomised human trials specifically testing eugenol against pain outcomes beyond its original dental application. Commercial source: Clove bud is the standard and dominant commercial source of eugenol, and Herbuno’s standardised extract reflects this well-established, genuine botanical match.

---

Evidence for Eugenol Applications

Eugenol acts as an agonist at the TRPV1 receptor, the same ion channel activated by capsaicin, which is understood to underlie both its local anaesthetic and its characteristic warming, spicy sensation; it is also a documented monoamine oxidase inhibitor and exhibits COX-2 and lipoxygenase-inhibiting anti-inflammatory activity, giving it a genuinely multi-mechanism pharmacological profile rather than a single narrow action. Claim strength: Moderate.

A 2025 systematic review of 21 clinical studies on phytotherapeutic agents for dental pain management identified eugenol (clove oil) as one of the most consistently evidenced natural analgesics across the reviewed literature, alongside ginger, for management of pulpitis, post-extraction pain and related dental conditions (Reddy et al. 2025). This makes eugenol one of the more clinically substantiated compounds in the HerbIQ index specifically for dental and oral applications. Claim strength: Moderate.

Beyond dentistry, a randomised, double-blinded, controlled cross-over trial in hemodialysis patients tested topical 4% eugenol nanoemulsion gel against placebo for pain caused by arteriovenous fistula needle cannulation, a procedure repeated multiple times weekly for these patients; the trial found that eugenol gel application significantly reduced cannulation-related pain intensity scores compared to placebo (Maghbool et al. 2020). This represents a genuine, non-dental human clinical application of eugenol’s local anaesthetic properties. Claim strength: Moderate.

For sustained-release delivery, researchers have developed mucoadhesive tablet formulations incorporating eugenol specifically for gingival application in periodontal disease management, exploiting eugenol’s established antibacterial, anti-inflammatory and local anaesthetic combination for extended local action rather than the brief exposure typical of direct oil application (et al. 2004). This reflects an active area of pharmaceutical formulation research building on eugenol’s traditional dental use. Claim strength: Moderate.

Formulators should be aware that eugenol carries a well-documented dose-dependent toxicity profile: while topical dental and low-concentration formulation use has an extensive safety history, concentrated or high-volume oral eugenol/clove oil exposure has been associated with hepatotoxicity and other adverse effects in case reports, particularly in young children, so concentration and intended-use context should always be specified clearly in any eugenol-containing product. Claim strength: Moderate.

---

Dosage & Formulator Specification

Dental and topical formulations have historically used eugenol at concentrations ranging from 1–15% depending on application (temporary dental cement versus dilute topical pain-relief gel), with the hemodialysis pain trial using a 4% topical nanoemulsion; there is no established oral ingestible dosing range given eugenol’s documented dose-dependent oral toxicity concerns.

Analytical quantification of eugenol is performed by GC or HPLC, the standard methods for clove oil quality control; formulators should request eugenol-specific chromatographic data since clove oil also contains related but distinct compounds such as eugenol acetate and beta-caryophyllene at varying levels depending on extraction method and plant material freshness.

Given eugenol’s TRPV1-agonist, capsaicin-like mechanism, formulators should apply the same general caution used for other warming/irritant topical actives regarding mucous membrane and broken skin exposure, and should reference established dental-cement and topical-formulation concentration precedent rather than assuming higher concentrations are proportionally more effective without increased irritation risk.

Regulatory positioning for eugenol follows established clove and dental-material precedent in most markets; it is FDA-recognised as GRAS for food flavouring use and has long-standing dental-material regulatory history. Formulators should note the documented case reports of hepatotoxicity from concentrated oral clove oil exposure, particularly relevant for any product accessible to or marketed toward children.

---

Frequently Asked Questions — Eugenol

Related compounds: Citral, Carvacrol